xenocyloin

A member of the class of indoles that is 1-H indole with the hydrogen at position 3 substituted with a 2'-hydroxy-3'-alkoxy-4'-alkyl group. It is an antiinsectan compound found in the nematode parasite Xenorhabdus bovienii.


An oxo-fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxylic acid group of 3-oxooctanoic acid.


prostaglandin antagonist

A compound that inhibits the action of prostaglandins.


name: Central Nervous System Solitary Fibrous Tumor, Grade 1

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A solitary fibrous tumor that arises from the central nervous system. It corresponds most often to the collagenous and low cellularity spindle cell tumor which was diagnosed as central nervous system solitary fibrous tumor in the past.


6-carboxyrhodamine 6G

A rhodamine 6G compound having a carboxy substituent in the 6-position.


Grade 2 Eyelid Dysfunction, CTCAE

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing


Stomach Mass

description: An abnormal growth located in the stomach.


DIPYRIDYL

A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'.


Gly-D-Thr

A dipeptide formed from glycine and D-threonine residues.


name: Other Stimulant Abuse with Intoxication Delirium

description: Evidence of other stimulant abuse with intoxication delirium not specified elsewhere.


3-methoxytyramine sulfate

An aryl sulfate that is 3-methoxytyramine in which the phenolic hydrogen has been replaced by a sulfo group.


name: Melanoma of the Conjunctiva pT4 TNM Finding v7

description: Melanoma of the conjunctiva with tumor invading the central nervous system.  (from AJCC 7th Ed.)


all-trans-retinyl oleate

A fatty acid ester formed between oleic acid and all-trans-retinol.


Pulmonary Function Test Normal

description: Results that are standard and expected for the reference population with any of the parameters used to measure the mechanical function of the lungs and associated structures.


A steroid saponin isolated from Ornithogalum thyrsoides and has been shown to exhibit cytotoxic activity.


A 4-(phosphonomethyl)phenylalanine that has D-configuration.


A phenylalanine derivative that is phenylalanine substituted by a phosphonomethyl group at position 4.


A 4-(phosphonomethyl)phenylalanine that has L-configuration.


name: Soft Tissue Sarcoma of the Retroperitoneum pM1 TNM Finding v8

description: Soft tissue sarcoma of the retroperitoneum with distant metastasis. (from AJCC 8th Ed.)


name: Soft Tissue Sarcoma of the Retroperitoneum Pathologic TNM Finding v8

description: A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system.


name: Soft Tissue Sarcoma of the Retroperitoneum pT1 TNM Finding v8

description: Soft tissue sarcoma of the retroperitoneum measuring 5 cm or less in greatest dimension. (from AJCC 8th Ed.)


name: Soft Tissue Sarcoma of the Retroperitoneum Pathologic Primary Tumor TNM Finding v8

description: A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor.


name: Soft Tissue Sarcoma of the Retroperitoneum Pathologic Regional Lymph Nodes TNM Finding v8

description: A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system as they pertain to staging of regional lymph nodes.


name: Soft Tissue Sarcoma of the Retroperitoneum pT3 TNM Finding v8

description: Soft tissue sarcoma of the retroperitoneum measuring more than 10 cm and less than or equal to 15 cm in greatest dimension. (from AJCC 8th Ed.)


name: Soft Tissue Sarcoma of the Retroperitoneum pT0 TNM Finding v8

description: Soft tissue sarcoma of the retroperitoneum with no evidence of primary tumor. (from AJCC 8th Ed.)


name: Soft Tissue Sarcoma of the Retroperitoneum pTX TNM Finding v8

description: Soft tissue sarcoma of the retroperitoneum in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)


name: Soft Tissue Sarcoma of the Retroperitoneum pN0 TNM Finding v8

description: Soft tissue sarcoma of the retroperitoneum without regional lymph node metastasis or unknown lymph node status. (from AJCC 8th Ed.)


name: Soft Tissue Sarcoma of the Retroperitoneum pN1 TNM Finding v8

description: Soft tissue sarcoma of the retroperitoneum with regional lymph node metastasis. (from AJCC 8th Ed.)


name: Soft Tissue Sarcoma of the Retroperitoneum pT4 TNM Finding v8

description: Soft tissue sarcoma of the retroperitoneum measuring more than 15 cm in greatest dimension. (from AJCC 8th Ed.)


name: Soft Tissue Sarcoma of the Retroperitoneum Pathologic Distant Metastasis TNM Finding v8

description: A pathologic finding about one or more characteristics of soft tissue sarcoma of the retroperitoneum, following the rules of the TNM AJCC v8 classification system as they pertain to distant metastases.


(E)-5-(2-methylphenyl)-4-pentenoic acid

This compound belongs to the class of organic compounds known as styrenes. These are organic compounds containing an ethenylbenzene moiety


name: Duodenum Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE


name: Grade 3 Duodenum Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE


name: Grade 2 Duodenum Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE


name: Grade 4 Duodenum Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE


name: Grade 5 Duodenum Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE


Zwitterionic form of N(6)-acetyl-N(6)-hydroxy-L-lysine arising from transfer of a proton from the carboxy to the amino group; major species at pH 7.3


An omega-hydroxy fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 16-hydroxyhexadecanoic acid.


manic episode in full remission

description: Evidence of manic episode in full remission.


A beta-D-glucoside that is the 5-aminopentyl glycoside of a tetrasaccharide consisting of beta-D-glucosyl, beta-D-galactosyl, beta-D-glucuronosyl and beta-D-glucosyl residues linked sequentially (1->4).


name: Familial Hemophagocytic Lymphohistiocytosis Type 4

description: Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the STX11 gene.


name: Familial Hemophagocytic Lymphohistiocytosis Type 2

description: Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the PRF1 gene.


name: Familial Hemophagocytic Lymphohistiocytosis Type 3

description: Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the UNC13D gene.


description: The reemergence of hemophagocytic lymphohistiocytosis after a period of remission.


description: Hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infection.


name: Familial Hemophagocytic Lymphohistiocytosis Type 5

description: Familial hemophagocytic lymphohistiocytosis caused by biallelic mutations in the STXBP2 gene.


description: Hemophagocytic lymphohistiocytosis associated with a viral infection.


name: Grade 2 Peritoneal Cavity Infection with Normal Absolute Neutrophil Count or Grade 1 or 2 Neutrophils, CTCAE


Refractory Fungal Infection

description: A fungal infection that is resistant to treatment.


Renal Benign Mesenchymoma

description: A benign mesenchymoma arising from the kidney.


4-oxo-4-(pyridin-3-yl)butanoic acid

A monocarboxylic acid that is succinic acid in which the hydroxy group of one of the carboxy groups is replaced by a pyridin-3-yl group.  A byproduct of tobacco-specific N-nitrosamines generated by cytochrome P-450 which catalyzes methylnitrosaminopyridylbutanone hydroxylation, this nicotine metabolite is commonly found in the urine of smokers.


Pulmonary Valve Vena Contracta Width

description: The width of the vena contracta of the pulmonic valve.


Mild Bronchopulmonary Dysplasia

description: A chronic lung disorder associated with pulmonary maldevelopment, scarring, and/or inflammation that develops in preterm neonates exposed to supplemental oxygen for at least 28 days. For infants born before 32 weeks gestation with mild BPD, there is no supplemental oxygen requirement at 36 weeks postmenstrual age or earlier discharge. For infants born after 32 weeks with mild BPD, there is no supplemental oxygen requirement at 56 days post-natal age or at earlier discharge.


H influenze type B Pneumonia

description: Pneumonia that is attributed to the bacteria H influenze type B.


Collapsed Lung

description: Atelectasis of an entire lung.


Community acquired pneumonia

description: Pneumonia that is not acquired in a hospital or long-term care facility setting.


name: Somatoform autonomic dysfunction - respiratory tract

description: A respiratory malfunction for which mental factors play a causative role.


Acute pneumonia

description: Acute inflammation of the lung parenchyma caused by viruses, bacteria, fungi, radiation treatment, or exposure to chemicals.  Signs and symptoms include cough, shortness of breath, fevers, chills, chest pain, headache, sweating, and weakness.


Non-Neoplastic Lung Disorder

description: A lung disorder not caused by a neoplasm. Representative examples include chronic obstructive pulmonary disease, atelectasis, lung infections, pulmonary fibrosis, and pneumoconiosis.


Bronchiolitis Obliterans Syndrome

description: Bronchiolitis obliterans following lung or allogeneic hematopoietic cell transplantation.


Follicular Bronchitis/Bronchiolitis

description: A non-neoplastic disorder characterized by the formation of reactive lymphoid follicles adjacent to distal bronchi and bronchioles.  It presents with mild shortness of breath and is associated with immunodeficiency syndromes and collagen vascular disorders.


COVID-19-Associated Pneumonia

description: Pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is characterized by the presence of ground glass opacities on CT scan images.


Congenital anomaly of lung

description: A malformation in the lung that is present at birth. Representative examples include pulmonary hypoplasia, pulmonary agenesis, congenital lobar emphysema, and alveolar capillary dysplasia.


Pulmonary alveolitis

description: Inflammation of the alveoli of the lung.


name: Respiratory Failure Related to Neuromuscular Disorder

description: Impaired gas exchange by the respiratory system resulting in hypoxemia and decreased oxygenation of the tissues that may be associated with increased arterial levels of carbon dioxide; the respiratory failure is due to a neuromuscular disorder.


Pulmonary cryptococcosis

description: Fungal pneumonia caused by inhalation of particles of Cryptococcus.  It usually occurs in immunocompromised patients such as persons with AIDS, transplant recipients, patients receiving cytotoxic chemotherapy, and patients with hematologic malignancies.  It is rare in immunocompetent individuals.  Signs and symptoms include fever, cough, and dyspnea.


name: Pneumonia caused by respiratory syncytial virus

description: Pneumonia that is attributed to the respiratory syncytial virus.


Hospital acquired pneumonia

description: Pneumonia acquired during a hospital stay.


Paracicatricial Emphysema

description: The development of dilated terminal airspaces in the lung adjacent to parenchymal scarring.


name: Chronic obstructive asthma (with obstructive pulmonary disease)

description: Chronic airway obstruction caused by asthma.


Pulmonary vascular disorder

description: A category of non-neoplastic disorders that affect the blood vessels in the lungs.  Representative examples include pulmonary embolism, pulmonary hypertension, and arteriovenous malformations.


Steroid-Refractory Pneumonitis

description: Pneumonitis that does not respond to corticosteroid therapy.


Tuberculous bronchiectasis

description: Bronchiectasis that develops in patients with a history of pulmonary tuberculosis.  It is usually associated with healed scars but occasionally may be seen in patients with active pulmonary tuberculosis.


Severe acute respiratory infection

description: A respiratory infectious disorder that leads to an acute illness that requires medical attention.


Stannosis

description: A disorder associated with chronic exposure to inhaled tin oxide dust or fumes.


Severe Bronchopulmonary Dysplasia

description: Bronchopulmonary dysplasia that results in severe respiratory complications. The infants with severe symptoms are usually premature, have low birth weight, and the oxygen and ventilation support requirements are increased.


name: Pneumonia caused by methicillin resistant Staphylococcus aureus

description: Pneumonia that is caused by Staphylococcus aureus that is resistant to methicillin treatment.


Cannabinosis

description: A disorder associated with chronic exposure to inhaled dust during the processing of hemp.


Asbestos-Related Lung Disorder

description: A disorder affecting the lungs due to asbestos exposure. Examples include asbestosis and lung carcinoma.


Toxoplasma Pneumonia

description: Pneumonia caused by the parasite Toxoplasma gondii.  It usually presents as an opportunistic infection in immunocompromised patients, especially patients with AIDS.  It is rare in immunocompetent individuals.  Signs and symptoms include cough, fever, and dyspnea.


Secondary Pneumonia

description: A pneumonia that occurs during or following treatment for an acute (primary) pneumonia that was caused by a different organism. It may be the result of increased susceptibility due to the initial treatment.


Pulmonary trunk hypoplasia

description: Underdeveloped pulmonary arteries.


Non-cardiogenic pulmonary edema

description: Pulmonary edema that is not a result of cardiac dysfunction.


name: Respiratory Failure Related to Central Nervous System Disorder

description: Impaired gas exchange by the respiratory system resulting in hypoxemia and decreased oxygenation of the tissues that may be associated with increased arterial levels of carbon dioxide; the respiratory failure is due to a central nervous system disorder.


name: Autoimmune Pulmonary Alveolar Proteinosis

description: A type of pulmonary alveolar proteinosis associated with low concentrations of GM-CSF.


Sickle Cell Chronic Lung Disease

description: A pulmonary complication of sickle cell disease characterized by radiographic interstitial abnormalities and impaired pulmonary function. In severe cases, pulmonary hypertension is present.


Atypical pneumonia

description: Historical term that references a form of pneumonia caused by Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella species.


Hyaline Membrane Syndrome

description: A serious disorder affecting newborns, particularly premature infants. It is caused by deficiency of surfactant, resulting in the formation of a membrane in the alveoli lining. This membrane contains fibrin and cellular debris and interferes with respiration. Infants with this disorder develop breathing problems immediately or in a few hours after delivery. It may lead to respiratory failure.


Fibrotic Hypersensitivity Pneumonitis

description: Interstitial lung fibrosis resulting from chronic hypersensitivity pneumonitis.


AIDS-Related Pneumocystis Pneumonia

description: A serious AIDS-related opportunistic infection of the lungs, caused by Pneumocystis jirovecii.  It is one of the most common AIDS-related illnesses and is a major cause of morbidity in patients with AIDS.  Signs and symptoms include cough, fever, dyspnea, and pain or tightness in the chest.


Pulmonary Precancerous Condition

description: A premalignant pathologic process that affects the lungs.  This category includes bronchial intraepithelial neoplasia and atypical adenomatous hyperplasia.


Acute pulmonary edema

description: Rapid or severe onset or rapid progression of pulmonary edema causing significant hypoxemia or the need for supplemental oxygen.


Diffuse Panbronchiolitis

description: A clinico-pathologic syndrome primarily affecting the respiratory bronchioles with evidence of inflammation in all layers of the bronchiole. Sinusitis is often an accompanying feature.


Grade 4 Venous Injury, CTCAE

description: Life-threatening consequences; evidence of end organ damage; urgent operative intervention indicated


A piperidinecarboxylate ester that is the methyl ester of 3-hydroxypiperidine-1-carboxylic acid.


Eyelid Carcinoma cN0 TNM Finding v8

description: Eyelid carcinoma with no evidence of lymph node involvement. (from AJCC 8th Ed.)


name: 2-[(2R,3S,6S)-3-amino-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]acetic acid methyl ester


Mesothelial hyperplasia

description: A hyperplasia of the mesothelial cells.


Atypical Mesothelial Hyperplasia

description: An atypical hyperplasia of the mesothelial cells.


Infectious Salpingitis

description: An acute or chronic infectious process affecting the fallopian tube. Chlamydia trachomatis, Neisseria gonorrhea, Mycoplasma, Staphylococcus, and Streptococcus are the most common causative agents.


celabenzine

A cyclic spermidine alkaloid that is 2-phenyl-1,5,9-triazacyclotridecan-4-one in which the amino hydrogen at position 9 has been replaced by a benzoyl group.


cadabicine sulfate

A spermidine alkaloid with formula C25H29N3O7S that is biosynthesised by Arabidopsis thaliana.


celafurine

A cyclic spermidine alkaloid that is 2-phenyl-1,5,9-triazacyclotridecan-4-one in which the amino hydrogen at position 9 has been replaced by a furan-3-carbonyl group.


celacinnine

A spermidine alkaloid that is isolated from Maytenus heterophylla and Maytenus senegalensis.


A beta-D-Glcp-(1->6)-D-Galp in which the carbon bearing the anomeric hydroxy group has beta configuration.


A glycosylgalactose consisting of a beta-D-glucopyranose residue and a D-galactopyranose residue joined in sequence by a (1->6) glycosidc bond.


A beta-D-Glcp-(1->6)-D-Galp in which the carbon bearing the anomeric hydroxy group has alpha configuration.


name: Attention and Concentration Deficit following Cerebral Infarction

description: Evidence of attention and concentration deficit following cerebral infarction.


Conjunctival Rhabdomyosarcoma

description: A rhabdomyosarcoma that arises from the conjunctiva.


glycycarpan

A member of the class of pterocarpan that is a cis-pterocarpan substituted by a hydroxy group at position 9, a 3-hydroxy-3-methylbutyl group at position 8, a methoxy group at position 1 and a dimethylpyran ring fused across positions 2 and 3. It has been isolated from Glycyrrhiza uralensis.


A 15-HETrE consisting of (8Z,11Z,13E)-icosatrienoic acid in which the 15-hydroxy group has S-configuration.


name: Diffuse Follicular Center Lymphoma, Lymph Nodes of Axilla and Upper Limb

description: Evidence of diffuse follicular center lymphoma, lymph nodes of axilla and upper limb.


7-demethylmitomycin B

A member of the family of mitomycins that is mitomycin B in which the methoxy group  on the quinone ring is replaced by a hydroxy group.


7-demethylmitomycin A

A member of the family of mitomycins that is mitomycin A in which the methoxy group on the quinone ring is replaced by a hydroxy group.


MITOMYCIN B

A member of the family of mitomycins that exhibits antibiotic and antitumour properties.


name: Thyroid Cancer pM1 TNM Finding v6 and v7

description: Thyroid cancer with distant metastasis. (from AJCC 6th and 7th Eds.)


(S)-pydiflumetofen

3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-(2,4,6-trichlorophenyl)propan-2-yl]pyrazole-4-carboxamide that is the (S)-enantiomer of pydiflumetofen.


A 2,3-diacyl-1-alpha-D-galactosyl-sn-glycerol in which the groups at the 1- and 2-positions are palmitoyl and oleoyl respectively.


onium betaine

Neutral molecules having charge-separated forms with an onium atom which bears no hydrogen atoms and that is not adjacent to the anionic atom.


An O-acylcarnitine having 13-carboxytridecanoyl as the acyl substituent.


O-arachidonoylcarnitine

An O-acylcarnitine having arachidonoyl as the acyl substituent.


An O-acyl-L-carnitine in which the acyl group specified is 2-hydroxypentanoyl.


An O-acylcarnitine having (2E,4Z)-decadienoyl as the acyl substituent.


O-hydroxyvaleroyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is hydroxyvaleroyl in which the position of the hydroxy group is unspecified.


An O-tetradecenoyl-L-carnitine  in which the acyl group is specified as (5Z)-tetradecenoyl.


O-(hydroxyhexadecadienoyl)carnitine

An  O-acylcarnitine having hydroxyhexadecadienoyl as the acyl substituent in which the position of the double bonds and the hydroxy group is unspecified.


O-acryloyl-L-carnitine

An O-acyl-L-carnitine having acryloyl as the acyl group.


O-acetylcarnitine

An O-acylcarnitine having acetyl as the acyl substituent.


D-proline betaine

An amino acid betaine that is D-proline zwitterion in which both of the hydrogens attached to the nitrogen are replaced by methyl groups.


acetonitrile oxide

The nitrile oxide resulting from the oxidation of the nitrogen atom of acetonitrile.


An O-acylcarnitine that is carnitine having a 3-hydroxyicosadienoyl group as the acyl substituent (positions of the double bonds are unspecified).


O-propanoyl-L-carnitine

An optically active O-acylcarnitine compound having propanoyl as the acyl substituent and (R)-configuration at the 3-position.


O-glutaconylcarnitine

An O-acylcarnitine in which the acyl group specified is glutaconyl.


saturated fatty acyl-L-carnitine

An O-acylcarnitine in which the R is a saturated fatty acyl chain.


An O-acylcarnitine having 3-hydroxypalmitoleoyl as the acyl substituent.


nitrile sulfide

Members of the class of  nitrilium betaine that include compounds having the structure R-C#NS.


O-valeroylcarnitine

A C5-acylcarnitine in which the acyl group specified is valeroyl.


NSDB 211

An ammonium betaine derivative of propanesulfonic acid. One of a group of non-detergent sulfobetaines having a sulfobetaine hydrophilic group and a short hydrophobic group that cannot aggregate to form micelles.


octenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a octenoyl group as the acyl substituent in which the position of the double bond is unspecified.


O-nonanoylcarnitine

A C9-acylcarnitine having nonanoyl as the acyl substituent.


O-sebacoylcarnitine

An O-acylcarnitine having sebacoyl as the acyl substituent.


An O-acylcarnitine having (2E)-7-carboxyhept-2-enoyl as the acyl substituent.


An O-acylcarnitine having (9Z)-3-hydroxydodecenoyl as the acyl substituent.


O-propenoyl-D-carnitine

An O-acyl-L-carnitine in which the acyl group specified is propenoyl.


O-(hydroxyhexadecanoyl)carnitine

An O-acylcarnitine that is carnitine having a hydroxyhexadecanoyl group as the acyl substituent in which the position of the hydroxy group is unspecified.


D-ribosylnicotinate

Conjugate base of D-ribosylnicotinic acid.


O-tetradecenoylcarnitine

An  O-acylcarnitine in which the acyl group specified is tetradecenoyl.


CEFTAROLINE

A cephalosporin that is the active metabolite of the prodrug ceftaroline fosamil.  Used for the treatment of adults with acute bacterial skin and skin structure infections.


An O-acylcarnitine in which the O-acyl group is specified as (3R,11Z,14Z)-3-hydroxyicosadienoyl.


6-(methylthio)hexanonitrile oxide

A nitrile oxide that is pentane in which two of the terminal methyl hydrogens at positions 1 and 5 have been replaced by oxidonitrile and methylsulfanyl groups.


O-methylmalonyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is methylmalonyl.


An O-acyl-L-carnitine that is L-carnitine having a 3-methylglutaryl group as the acyl substituent


An O-acyl-L-carnitine in which the acyl group is specified as 3-hydroxyvaleryl.


fatty acylcarnitine

Any O-acylcarnitine in which the acyl group is a fatty acid and the carnitine component has configuration undefined.


O-pimeloylcarnitine

An O-acylcarnitine having pimeloyl as the acyl substituent.


An O-acyl-L-carnitine in which the acyl group is specified as 3-oxopalmitoyl.


O-adipoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is adipoyl.


An O-acylcarnitine having 3-hydroxybutyryl as the acyl substituent.


O-nonanoyl-L-carnitine

The L-enantiomer of  O-nonanoylcarnitine.


O-hydroxytetradecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxytetradecenoyl group as the acyl substituent in which the positions of the hydroxy group and the double bond are unspecified.


An O-hexadecenoylcarnitine having (2E)-hexadecenoyl as the acyl substituent.


O-(hydroxyvaleryl)carnitine

An O-acylcarnitine having hydroxyvaleryl as the acyl substituent in which the position of the hydroxy group is unspecified.


An O-acylcarnitine having 17-carboxyheptadecanoyl as the acyl substituent.


nitrilium betaine

Derivatives of nitriles having the general structure R-C#N(+)-Y(-). A subclass of 1,3-dipolar compounds including nitrile imides, nitrile oxides, nitrile sulfides and nitrile ylides.


O-propenoylcarnitine

An O-acyl carnitine in which the acyl group specified is propenoyl.


cis-4-hydroxy-D-proline betaine

An amino-acid betaine that is trans-4-hydroxy-D-proline zwitterion in which both of the hydrogens attached to the nitrogen have been replaced by methyl groups.


An O-acylcarnitine having (11Z)-eicoseneoyl as the acyl substituent.


An O-acyl-L-carnitine in which the acyl group is specified as 4,8-dimethylnonanoyl.


An O-methylglutarylcarnitine compound having 3-methylglutaryl as the acyl substituent.


An O-acylcarnitine having (9Z)-17-carboxyheptadec-9-enoyl as the acyl substituent.


An O-acylcarnitine having (2E)-hexenedioyl as the acyl substituent.


O-malonyl-D-carnitine

An O-acyl-D-carnitine in which the acyl group specified is malonyl.


An O-hydroxytetradecenoylcarnitine having (9Z)-3-hydroxytetradec-9-enoyl as the acyl substituent.


(R)-oleoylcarnitine

An O-acyl-L-carnitine in which the acyl group is specified as oleoyl.


An O-tetradecadienoylcarnitine  having (5Z,8Z)-tetradecadienoyl as the acyl substituent.


THIAMIN DIPHOSPHATE

An ammonium betaine that is the conjugate base of thiamine(1+) diphosphate arising from the deprotonation of one of the hydroxy groups of the terminal phosphate group.


S,S-dimethyl-beta-propiothetin

A sulfonium betaine obtained by deprotonation of the carboxy group of 3-dimethylsulfoniopropionic acid.


O-methylmalonylcarnitine

An O-acylcarnitine having methylmalonyl as the acyl substituent.


An O-acylcarnitine having (9Z)-3-hydroxyoctadecenoyl as the acyl substituent.


Any O-acylcarnitine in which the acyl group contains a total of 5 carbon atoms.


O-isobutyryl-L-carnitine

An optically active form of O-isobutyrylcarnitine having (R)-configuration.


O-pimelylcarnitine

An O-acylcarnitine in which the acyl group specified is pimelyl.


An O-acylcarnitine having 3-hydroxyhexadecanoyl as the acyl substituent.


O-(dimethylnonenoyl)carnitine

An O-acylcarnitine in which the acyl group is specified as dimethylnonenoyl (positions of double bond and methyl groups not specified).


O-octadecadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a octadecadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.


O-propanoyl-D-carnitine

An O-acyl-D-carnitine in which  the acyl group specified is propanoyl.


O-palmitoleoylcarnitine

An O-acylcarnitine having palmitoleoyl as the acyl substituent.


O-malonylcarnitine

An O-acylcarnitine having malonyl as the acyl substituent.


diazonium betaine

An onium betaine having a diazonium as the positively charged component.


O-linoelaidylcarnitine

An O-octadecadienoylcarnitine having linoelaidyl as the acyl substituent.


O-lauroyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as lauroyl (dodecanoyl).


Major species at pH 7.3


O-(hydroxytetradecadienoyl)-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxytetradecadienoyl group as the acyl substituent in which the positions of the two double bonds and the hydroxy group are unspecified.


O-hexenoylcarnitine

An O-acyl carnitine in which the acyl group specified is hexenoyl.


O-acylcarnitine

Any carboxylic ester obtained by the O-acylation of carnitine.


D-phenylalanine betaine

A D-phenylalanine derivative obtained by trimethylation of the amino function of D-phenylalanine.


polyunsaturated fatty acyl-L-carnitine

Any fatty acyl-L-carnitine where the fatty acid has 2 or more unsaturations. Major species at pH 7.3


O-hydroxyhexanoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxyhexanoyl group as the acyl substituent in which the position of the hydroxy group is unspecified.


thiaminium carboxylate betaine

An ammonium betaine that is the conjugate base of thiamine(1+) carboxylic acid arising from the deprotonation of the carboxy group.


An O-acyl-D-carnitine in which the acyl group is specified as (11E)-octadecenoyl.


O-hexenoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is hexenoyl in which the position of the double bond is unspecified.


A O-hydroxyhexadecenoyl-L-carnitine in which the acyl group specified is 3-hydroxy-(9Z)-hexadecenoyl.


O-tetradecadienoylcarnitine

An O-acylcarnitine in which the acyl group specified is tetradecadienoyl.


An O-acylcarnitine having 3-hydroxytetradecanoyl as the acyl substituent.


O-decadienoylcarnitine

An O-acylcarnitine in which the acyl group specified is decadienoyl in which the positions of the double bonds is unspecified..


O-hydroxybutyryl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxybutyryl group as the acyl substituent in which the positions of  the hydroxy group is unspecified.


A C5-acylcarnitine having 2-methylbutyryl as the acyl substituent.


amino-acid betaine

Any amino acid-derived zwitterion - such as glycine betaine (N,N,N-trimethylammonioacetate) - in which the ammonium nitrogen carries methyl substituents and bears no hydrogen atoms.


2,6-dimethylheptanoyl carnitine

A C9-acylcarnitine in which the acyl group specified is 2,6-dimethylheptanoyl.


O-valeroyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is valeroyl.


fatty acyl-L-carnitine

Any O-acylcarnitine in which the carnitine component has L-configuration and the acyl group is a fatty acid.


An O-(hydroxytetradecadienoyl)carnitine having (5Z,8Z)-3-hydroxytetradecadienoyl as the acyl substituent.


An O-acylcarnitine having 3-hydroxydodecanoyl as the acyl substituent.


Cy3B dye NHS ester

A fluorescent dye with a maximum emission wavelength of 572 nm, derived from a heteroheptacyclic ring system.


O-dodecenoylcarnitine

An O-acylcarnitine in which the acyl group specified is dodecenoyl.


O-glutaroyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as glutaroyl.


An O-tetradecenoyl-L-carnitine in which the acyl group is specified as myristoleoyl.


O-butenoylcarnitine

An O-acyl carnitine in which the acyl group specified is butenoyl.


(R)-acetoacetylcarnitine

An O-acyl-L-carnitine in which the acyl group is specified as acetoacetyl.


O-methylglutarylcarnitine

An O-acylcarnitine in which the acyl group specified is methylglutaryl.


O-pimelyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a pimelyl group as the acyl substituent.


An amino-acid betaine obtained by deprotonation of the carboxy group of any N(5),N(5),N(5)-trimethyl-N(2)-[(3R)-3-(acyloxy)acyl]-L-ornithine; major species at pH 7.3.


S-methyl-L-ergothioneine

An amino acid betaine that is ergothioneine in which the hydrogen attached to the sulfur is replaced by a methyl group. It has been isolated from the deepwater (500-1,600 m) marine sponge Macandrewia azorica.


CARNITINE

An amino-acid betaine that is butanoate substituted with a hydroxy group at position C-3 and a trimethylammonium group at C-4.


O-(hydroxyoctadecenoyl)carnitine

An O-acylcarnitine having hydroxyoctadecenoyl as the acyl group in which the position of the double bond and hydroxy group are unspecified.


O-hexadecenedioylcarnitine

An O-acylcarnitine that is carnitine having a hexadecenedioyl group as the acyl substituent (position of the double bond is unspecified).


O-hexanoylcarnitine

An O-acylcarnitine compound having hexanoyl as the acyl substituent.


O-octadecadiendioylcarnitine

An O-acylcarnitine obtained by formal condensation of one of the carboxy groups of any  octadecadiendioic acid with the hydroxy group of carnitine.


An O-acylcarnitine having (13Z,16Z)-docosadienoyl as the acyl substituent.


An O-acylcarnitine having (5Z)-tetradecenoyl as the acyl substituent.


An  octenoyl-Lcarnitine having 2-octenoyl as the acyl substituent.


methyl-branched fatty acyl-L-carnitine

An O-acylcarnitine in which the R group is a methyl-branched fatty acyl chain.


O-(hydroxypropionyl)carnitine

An O-acylcarnitine in which the acyl group specified is hydroxypropionyl.


NDSB 221

An ammonium betaine derivative of 3-(piperidin-1-yl)propane-1-sulfonic acid. One of a group of non-detergent sulfobetaines having a sulfobetaine hydrophilic group and a short hydrophobic group that cannot aggregate to form micelles.


Major species at pH 7.3


An O-acylcarnitine having (11Z,14Z)-eicosadienoyl as the acyl substituent.


An O-acylcarnitine having 3-hydroxylinoleoyl as the acyl substituent.


O-octanoyl-D-carnitine

An O-acyl-D-carnitine in which the acyl group specified as octanoyl.


An O-acylcarnitine compound having 4,8-dimethylnonanoyl as the acyl substituent.


O-malonyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as malonyl.


An O-acylcarnitine having 3-hydroxyeicosanoyl as the acyl substituent.


O-fumarylcarnitine

An O-acylcarnitine in which the acyl group specified is fumaryl.


O-hydroxyhexadecadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxyhexadecadienoyl group as the acyl substituent in which the positions of the two double bonds and the hydroxy group are unspecified.


An O-acylcarnitine having 3-hydroxyoctanoyl as the acyl substituent.


O-tetradecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having tetradecenoyl group as the acyl substituent in which the position of the double bond is unspecified.


A non-proteinogenic dipeptide formed from L-gamma-glutamic acid and hercynyl-L-cysteine sulfoxide residues. It is an intermediate in the synthesis of ergothioneine, a compound found in certain fungi and mycobacteria.


O-tetradecadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a tetradecadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.


An O-acylcarnitine in which the acyl group is specified as (4E,7E,10E,13E,16E)-docosapentaenoyl.


nitrile oxide

Compounds having the structure R-C#NO.


O-palmitoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as palmitoyl (hexadecanoyl).


O-icosanoylcarnitine

An O-acylcarnitine having icosanoyl (arachidoyl) as the acyl substituent.


O-dodecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having dodecenoyl group as the acyl substituent in which the position of the double bond is unspecified.


An O-(hydroxyhexadecadienoyl)carnitine having (9Z,12Z)-3-hydroxyhexadecadienoyl as the acyl substituent.


O-linoleoylcarnitine

An O-acylcarnitine having linoleoyl as the acyl substituent.


trans-4-hydroxy-L-proline betaine

An amino-acid betaine that is trans-4-hydroxy-L-proline zwitterion in which both of the hydrogens attached to the nitrogen have been replaced by methyl groups.


An O-acylcarnitine having 3-hydroxyarachidonoyl as the acyl substituent.


O-(hydroxytetradecadienoyl)carnitine

An O-acylcarnitine in which the acyl group specified is hydroxytetradecadienoyl.


An O-acylcarnitine having 3-hydroxyisovaleryl as the acyl substituent.


An O-acylcarnitine having 3-hydroxy-cis-5-octenoyl as the acyl substituent.


O-glutaconyl-L-carnitine

An O-acyl-L-carnitine where the acyl group specified is glutaconyl.


An O-acylcarnitine having (2E,5Z,7E)-decatrienoyl as the acyl substituent.


monounsaturated fatty acyl-L-carnitine

An O-acylcarnitine in which the R is a monounsaturated fatty acyl chain.


Major species at pH 7.3


O-nonadecanoylcarnitine

An O-acylcarnitine having nonadecanoyl as the acyl substituent.


fenmezoditiaz

An iminium betaine that is 2,3,7,8-tetrahydro[1,3]thiazolo[3,2-a]pyrimidin-4-ium substituted by a 2-chloro-1,3-thiazol-5-yl, oxidanidyl, phenyl, oxo, and methyl groups at positions 3R, 5, 6, 7 and 8, respectively. It is a mesoionic insecticide developed by BASF.


Published in DOI:10.1080/00021369.1989.10869245. Major species at pH 7.3.


O-dodecanoylcarnitine

An O-acylcarnitine having dodecanoyl as the acyl substituent.


O-decanoylcarnitine

An O-acylcarnitine compound having decanoyl as the acyl substituent.


O-acyl-D-carnitine

An O-acylcarnitine in which the carnitine component has D-configuration.


An O-acylcarnitine having (5Z)-13-carboxytridec-5-enoyl as the acyl substituent.


O-decanoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having decanoyl as the acyl substituent.


O-isovalerylcarnitine

A C5-acylcarnitine having isovaleryl as the acyl substituent.


An O-tetradecenoylcarnitine  having 2-tetradecenoyl as the acyl substituent.


An O-tetradecenoyl-L-carnitine obtained by formal condensation of the carboxy group of (5E)-tetradecenoic acid with the hydroxy group of L-carnitine.


L-proline betaine

An amino acid betaine that is L-proline zwitterion in which both of the hydrogens attached to the nitrogen are replaced by methyl groups.


An O-hydroxybutyryl-L-carnitine in which the acyl group is specified as 3-hydroxybutyryl.


O-pentadecanoylcarnitine

An O-acylcarnitine in which the acyl group is specified as pentadecanoyl.


O-decenoylcarnitine

An O-acylcarnitine in which the acyl group is specified as decenoyl (position of double bond not specified).


O-(hydroxyhexadecanoyl)-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxyhexadecanoyl group as the acyl substituent in which the position of the hydroxy group  is unspecified.


L-phenylalanine betaine

An L-phenylalanine derivative obtained by trimethylation of the amino function of L-phenylalanine.


O-butenoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is butenoyl in which the position of the double bond is unspecified.


A sulfonium betaine obtained by deprotonation of the carboxy groups and protonation of the amino group of S-adenosyl-S-carboxymethyl-L-homocysteine. Major microspecies at pH 7.3


choline sulfate

An ammonium betaine that is the conjugate base of choline hydrogen sulfate, obtained by deprotonation of the sulfate OH group.


thiamine(1+) triphosphate(1-)

An ammonium betaine that is the conjugate base of thiamine(1+) triphosphate arising from the deptoronation of one of the hydroxy groups of the terminal phosphate group.


O-oleoylcarnitine

An O-acylcarnitine having oleoyl as the acyl substituent.


Hypaphorine

An amino acid betaine obtaine by exhaustive methylation of the alpha-amino group of L-tryptophan with concomitant deprotonation of the carboxy group.


CYNOOXIDE ANION

A nitrile oxide resulting from the oxidation of hydrogen cyanide.


O-glutarylcarnitine

An O-acylcarnitine having glutaryl as the acyl substituent.


O-dodecanedioylcarnitine

An O-acylcarnitine having 11-carboxyundecanoyl as the acyl substituent.


O-hydroxyoctadecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxyoctadecenoyl group as the acyl substituent in which the position of the double bond and the hydroxy group is unspecified.


An optically active form of O-2-methylbutyrylcarnitine having (R)-configuration.


O-decenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having decenoyl group as the acyl substituent in which the position of the double bond is unspecified.


O-hexadecenoylcarnitine

An  O-acylcarnitine having a hexadecenoyl group with an unspecified double bond as the acyl substituent.


beta-alanine betaine

A beta-alanine derivative arising from quaternisation of the nitrogen of beta-alanine with three methyl groups and removal of the proton attached to the carboxy group. It is an osmoprotective compound accumulated by most members of the highly stress-tolerant Plumbaginaceae family.


D-CARNITINE

The (S)-enantiomer of carnitine.


O-octenedioylcarnitine

An O-acylcarnitine obtained by formal condensation of one of the carboxy groups of any octenedioic acid with the hydroxy group of carnitine.


nitrile ylide

A 1,3-dipolar compound having the structure: RC#N(+)-C(-)R2 <-> RC(-)=N(+)=CR2 <-> RC(+)=NC(-)R2 <-> R(.)C(.)-N=CR2.


D-tyrosine betaine

A D-tyrosine derivative obtained by trimethylation of the amino function of D-tyrosine.


5-hydroxyectoine zwitterion

An iminium betaine resulting from a transfer of a proton from the carboxy group to the imino group of 5-hydroxyectoine.  It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).


O-hexanoyl-L-carnitine

An O-hexanoylcarnitine that has L configuration.


O-adipoylcarnitine

An O-acylcarnitine compound having adipoyl as the acyl substituent.


An O-dodecenoylcarnitine having (5Z)-dodecenoyl as the acyl substituent.


O-hexadecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hexadecenoyl group as the acyl substituent in which the position of the double bond is unspecified.


O-stearoylcarnitine

An O-acylcarnitine having stearoyl (octadecanoyl) as the acyl substituent.


(S)-carnitinyl-CoA betaine

A 3-hydroxyacyl-CoA where the S-acyl group is specified as (S)-carnitinyl.


thiamine(1+) monophosphate(1-)

An ammonium betaine that is the conjugate base of thiamine(1+) monophosphate arising from the deprotonation of one of the phosphate hydroxy groups.


hydroxy-fatty acyl-L-carnitine

An O-acylcarnitine in which the R group is a hydroxylated fatty acyl chain.


An O-acylcarnitine having 11-carboxyundecanoyl as the acyl substituent.


O-(hydroxytetradecenoyl)carnitine

An O-acylcarnitine in which the acyl group specified is hydroxytetradecenoyl.


O-heptenoylcarnitine

An O-acylcarnitine that is the O-heptenoyl derivative of carnitine.


N-diazoacetylnorleucine methyl ester

A  diazonium betaine obtained by the deprotonation of the hydroxy group of (Z)-2-hydroxy-2-{[(2S)-1-methoxy-1-oxohexan-2-yl]amino}ethenediazonium.


O-octadecadienoylcarnitine

An O-acylcarnitine in which the acyl group specified is octadecadienoyl.


O-acyl-L-carnitine

An O-acylcarnitine in which the carnitine component has L-configuration.


(+)-(S)-alapyridaine

An iminium betaine that is L-alanine in which the amino group is replaced by a 5-hydroxy-2-(hydroxymethyl)pyridinium-1-yl moiety.


O-heptanoylcarnitine

An  O-acylcarnitine that is the O-heptanoyl derivative of carnitine.


tyrosine betaine

An amino acid betaine derived from tyrosine.


O-heptadecanoylcarnitine

An O-acylcarnitine in which the acyl group is specified as heptadecanoyl.


oxo-fatty acyl-L-carnitine

An O-acyl-L-carnitine obtained by formal condensation of the carboxy group of any oxo-fatty acid with the hydroxy group of L-carnitine.


O-hexadecadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hexadecadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.


An O-decenoylcarnitine having (4Z)-decenoyl as the acyl substituent.


O-undecenoylcarnitine

An O-acylcarnitine in which the acyl group is specified as undecenoyl (position of double bond not specified).


phenylalanine betaine

An amino acid betaine derived from phenylalanine.


An O-acylcarnitine having (2E)-octenoyl as the acyl substituent.


An O-acylcarnitine having (9Z,12Z,15Z)-3-hydroxyoctadecatrienoyl as the acyl substituent.


O-octenoylcarnitine

An O-acylcarnitine in which the acyl group specified is octenoyl.


An O-octadecenoylcarnitine in which the acyl group is specified as (9E)-octadec-9-enoyl.


An O-acylcarnitine having 15-carboxypentadecanoyl as the acyl substituent.


nitrile selenide

Members of the class of nitrilium betaine that are compounds having the structure R-C#NSe.


O-hydroxypropionyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group specified is hydroxypropionyl in which the position of the hydroxy group is unspecified..


O-tiglyl-L-carnitine

An O-acyl-L-carnitine compound having trans-2-methyl-2-butenoyl (tiglyl) as the acyl substituent.


An O-acylcarnitine having 3-hydroxydecanoyl as the acyl substituent.


O-decadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having decadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.


A non-proteinogenic dipeptide formed from L-gamma-glutamic acid and hercynyl-L-selenocysteine residues.


O-dodecadienoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a dodecadienoyl group as the acyl substituent in which the positions of the two double bonds are unspecified.


An N-glycosylpyridine that is the N-alpha-D-glucosiduronyl derivative of (S)-nicotine.


(R)-icosanoylcarnitine

An O-acyl-L-carnitine in which the acyl group is specified as icosanoyl.


An O-acylcarnitine in which the acyl group is specified as (4E,7E,10E,13E,16E,19E)-docosahexaenoyl.


Any O-acylcarnitine in which the acyl group contains a total of 4 carbon atoms.


O-isobutyrylcarnitine

An O-acylcarnitine having isobutyryl as the acyl substituent.


sulfonium betaine

Neutral molecules having charge-separated forms with an sulfonium atom which bears no hydrogen atoms and that is not adjacent to the anionic atom.


O-tiglylcarnitine

An O-acylcarnitine compound having trans-2-methyl-2-butenoyl (tiglyl) as the acyl substituent.


An O-acylcarnitine having (7Z,10Z,13Z,16Z)-docosatetraenoyl as the acyl substituent.


O-butanoyl-L-carnitine

An optically active form of O-butanoylcarnitine having L-configuration.


Major species at pH 7.3.


O-octadecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a octadecenoyl group as the acyl substituent in which the position of the double bond is unspecified.


ceftaroline fosamil

A cephalosporin having [4-(1-methylpyridinium-4-yl)-1,3-thiazol-2-yl]sulfanyl and {(2Z)-2-(ethoxyimino)-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl}amino side groups located at positions 3 and 7 respectively. The N-phospho prodrug of ceftaroline, a broad-spectrum antibiotic active against methicillin-resistant Staphylococcus aureus (MRSA). It is used for the treatment of adults with acute bacterial skin and skin structure infections.


O-pivaloylcarnitine

A C5-acylcarnitine in which the acyl group specified is pivaloyl.


O-behenoylcarnitine

An O-acylcarnitine having behenoyl (docosanoyl) as the acyl substituent.


7-(methylthio)heptanonitrile oxide

A nitrile oxide that is hexane in which two of the terminal methyl hydrogens at positions 1 and 6 have been replaced by oxidonitrile and methylsulfanyl groups.


An O-acylcarnitine in which the acyl group is specified as 2-octadecenoyl.


O-fumaryl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as fumaryl.


O-octadecenoylcarnitine

An  O-acylcarnitine in which the acyl group specified is octadecenoyl.


O-(hydroxyhexadecenoyl)carnitine

An O-acylcarnitine having a hydroxyhexadecenoyl group as the acyl substituent in which the position of the hydroxy group and the double bond is unspecified.


O-tetradecanoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as myristoyl (tetradecanoyl).


ammonium betaine

Any neutral molecule having charge-separated forms with a quaternary ammonium atom which bears no hydrogen atoms and that is not adjacent to the anionic atom.


O-tetradecanoylcarnitine

An O-acylcarnitine having tetradecanoyl (myristoyl) as the acyl substituent.


Any O-acylcarnitine in which the acyl group contains a total of 9 carbon atoms.


Butyryl-carnitine

A C4-acylcarnitine  that is the O-butanoyl derivative of carnitine.


isovaleryl-L-carnitine

An O-isovalerylcarnitine that is the 3-methylbutanoyl (isovaleryl) derivative of L-carnitine.


O-suberoylcarnitine

An O-acylcarnitine having suberoyl (7-carboxyheptanoyl) as the acyl substituent.


O-hydroxyhexadecenoyl-L-carnitine

An O-acyl-L-carnitine that is L-carnitine having a hydroxyhexadecenoyl group as the acyl substituent in which the position of the hydroxy group and the double bond is unspecified.


O-octadecanoyl-L-carnitine

An O-acyl-L-carnitine in which the acyl group is specified as stearoyl (octadecanoyl).


L-tyrosine betaine

An L-tyrosine derivative obtained by trimethylation of the amino function of L-tyrosine.


O-octanoyl-L-carnitine

The L-enantiomer of an O-octanoylcarnitine.


An optically active form of 2,6-dimethylheptanoylcarnitine having (R)-configuration.


An O-acylcarnitine having 3-hydroxyoctadecanoyl as the acyl substituent.


An O-acylcarnitine having (7Z,10Z,13Z,16Z,19Z)-docosapentaenoyl as the acyl substituent.


An ammonium betaine that is the conjugate base of 3-dehydrocarnitinium; major species at pH 7.3.


name: Grade 4 Intra-Abdominal Hemorrhage, CTCAE

description: Life-threatening consequences; urgent intervention indicated


name: Unspecified Juvenile Rheumatoid Arthritis, Unspecified Ankle and Foot

description: Evidence of unspecified juvenile rheumatoid arthritis in an unspecified ankle and foot.


N-acetyl-alpha-D-muramoyl-L-alanine

A glyco-amino acid compound consisting of an N-acetyl-alpha-D-muramoyl group attached to L-alanine via an amide linkage.


GUANAZOLE

An aromatic amine that is 1,2,4-triazole substituted at positions 3 and 5 by amino groups.


name: Grade 3 Peristomal Infection Documented Clinically or Microbiologically with Grade 3 or 4 Neutrophils, CTCAE


VARESPLADIB METHYL

A methyl ester resulting from the formal condensation of the carboxy group of varespladib with methanol. It is a potential therapy for the treatment of snakebite envenomings in which toxicity depends on the action of PLA2s.


Grade 3 Rectal Hemorrhage, CTCAE

description: Transfusion indicated; invasive intervention indicated; hospitalization


Rectal Hemorrhage, CTCAE

description: A disorder characterized by bleeding from the rectal wall and discharged from the anus.


Grade 1 Rectal Hemorrhage, CTCAE

description: Mild symptoms; intervention not indicated


Grade 5 Rectal Hemorrhage, CTCAE

description: Death


Grade 2 Rectal Hemorrhage, CTCAE

description: Moderate symptoms; intervention indicated


A long-chain fatty alcohol that is tetradecan-1-ol bearing a methyl substituent at position 13.


name: Stage IA Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: pT1, N0, M0, S0. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Immature Teratoma

description: An immature teratoma occurring in children.


name: Localized Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Tumor confined to the testes. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Choriocarcinoma

description: A choriocarcinoma occurring in children.


name: Stage III Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, Any N, M1, SX. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Testicular Yolk Sac Tumor, Prepubertal-Type

description: Testicular yolk sac tumor that almost always occurs in pure form and is not associated with germ cell neoplasia in situ. It affects young children and is the most frequently seen testicular neoplasm in prepubertal children.


Childhood Mature Teratoma

description: A mature teratoma occurring in children.


name: Refractory Childhood Malignant Germ Cell Tumor

description: A malignant germ cell tumor that occurs during childhood and is resistant to treatment.


name: Stage IIIC Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N1-N3, M0, S3 or Any pT, Any N, M1, S3. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Stage IIIB Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N1-N3, M0, S2 or Any pT, Any N, M1, S2. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Childhood Malignant Testicular Germ Cell Tumor

description: A malignant germ cell tumor in children arising from the testis.  It includes the embryonal carcinoma, yolk sac tumor, choriocarcinoma, and mixed germ cell tumors.


name: Recurrent Childhood Malignant Germ Cell Tumor

description: The reemergence of a malignant germ cell tumor in children after a period of remission.


name: Stage IB Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: pT2-4, N0, M0, S0. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Germinomatous Germ Cell Tumor

description: A germinomatous germ cell tumor occurring in children.


Childhood Mixed Germ Cell Tumor

description: A mixed germ cell tumor occurring in children.


name: Stage IIA Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N1, M0, S0, S1. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Stage II Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N1-3, M0, SX. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Extracranial Germ Cell Tumor

description: A childhood benign or malignant germ cell tumor arising from an anatomic site other than the brain.


name: Metastatic Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Distant metastases present. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Teratoma

description: A mature or immature teratoma occurring in children.


Childhood Seminoma

description: A seminoma occurring in children.


Childhood Embryonal Carcinoma

description: An embryonal carcinoma occurring in children.


Childhood Extragonadal Teratoma

description: An extragonadal teratoma that occurs during childhood.


name: Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2 Stage, Tier 2

description: A term that refers to the staging of childhood testicular germ cell tumor according to the tier 2 Toronto childhood cancer staging guidelines v2.


name: Regional Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Tumor extension to regional lymph nodes: interaortocaval, para-aortic (periaortic), paracaval, preaortic, precaval, retroaortic, retrocaval, and along spermatic cord. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Stage IIB Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N2, M0, S0, S1. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Childhood Extragonadal Malignant Germ Cell Tumor

description: A malignant germ cell tumor in children arising from an anatomic site other than the testis or ovary.


name: Childhood Central Nervous System Teratoma

description: A mature or immature teratoma affecting the central nervous system and occurring in children.


Childhood Benign Germ Cell Tumor

description: A germ cell tumor that occurs during childhood and is characterized by the absence of atypia and metastatic potential.


name: Childhood Nongerminomatous Germ Cell Tumor

description: A nongerminomatous germ cell tumor occurring in children.


name: Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2 Stage, Tier 1

description: A term that refers to the staging of childhood testicular germ cell tumor according to the tier 1 Toronto childhood cancer staging guidelines v2.


name: Childhood Testicular Non-Seminomatous Germ Cell Tumor

description: A non-seminomatous germ cell tumor that arises in the testis and occurs in children.


name: Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2 Stage

description: A term that refers to the staging of childhood testicular germ cell tumor according to the Toronto childhood cancer staging guidelines v2.


name: Stage IS Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N0, M0, S1-3. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Stage I Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: pT1-4, N0, M0, SX. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


name: Stage IIC Childhood Testicular Germ Cell Tumor by Toronto Guidelines v2

description: Any pT, N3, M0, S0, S1. (Childhood cancer staging for population registries according to the Toronto Childhood Cancer Stage Guidelines - Version 2. Cancer Council Queensland and Cancer Australia: Brisbane, Australia; 2021.)


Childhood Testicular Yolk Sac Tumor

description: A yolk sac tumor that arises from the testis during childhood.


A galactosiduronic acid in which beta-D-galacturonic acid is linked glycosidically to a 3-aminopropyl group.


HOMOSERINE LACTONE

The L-enantiomer of homoserine lactone.


name: Carcinoma in Situ of Skin of Unspecified Lower Limb, Including Hip

description: Evidence of carcinoma in situ of the skin of unspecified lower limb including the hip.


name: Quercetin 5,7,3',4'-tetramethyl ether 3-galactoside


Tetanic contractions of uterus

description: A single uterine contraction lasting greater than 2 minutes.


The (R)-enantiomer of 2-benzylsuccinyl-CoA.


omega-carboxyacyl-CoA

An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of any alpha,omega-dicarboxylic acid.


succinyl-CoA

An omega-carboxyacyl-CoA having succinoyl as the S-acyl component.


A 3-hydroxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 3-hydroxypimelic acid.


An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 2-benzylsuccinic acid.


pimeloyl-CoA

An omega carboxyacyl-CoA that is the S-pimeloyl derivative of coenzyme A.


oxalyl-CoA

An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of oxalic acid.


mesaconyl-CoA

An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the 1-carboxy group of mesaconic acid.


(R)-ethylmalonyl-CoA

An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of (R)-ethylmalonic acid.


An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the least hindered carboxy group of mesaconic acid.


(S)-ethylmalonyl-CoA

An acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of (2S)-ethylmalonic acid.


The S-3-hydroxy-3-(4-methylpent-3-en-1-yl)glutaryl derivative of CoA.


decanedioyl-CoA

An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of decanedioic acid.


adipoyl-CoA

An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of adipic acid.


A 3-hydroxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the 3-carboxy group of 3-carboxy-3-hydroxypropanoic acid.


octanedioyl-CoA

An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of octanedioic acid.


A 3-hydroxy-3-methylglutaryl-CoA where the 3-hydroxy-3-methylglutaryl component has (S)-configuration.


glutaryl-CoAs

Any  omega-carboxyacyl-CoA in which the acyl group specified is glutaryl or its substituted derivative.


An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of 3-hydroxy-3-methylglutaric acid.


glutaryl-CoA

An omega-carboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of glutaric acid.


dodecanedioyl-CoA

An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of dodecanedioic acid.


Intermediate Grade Osteosarcoma

description: An osteosarcoma with intermediate-grade morphological features. A representative example is periosteal osteosarcoma.


name: Peripheral Nervous System Infectious Disorder

description: An infectious process affecting the peripheral nerves.


A glycosylmannose consisting of two D-mannopyranose residues joined via an alpha-(1->3)-linkage.


Grade 5 Renal Calculi, CTCAE

description: Death


name: (6S)-6-hydroxy-1,4,5,6-tetrahydronicotinamide adenine dinucleotide 2'-phosphate


name: tetrahydronicotinamide adenine dinucleotide phosphate

description: A nicotinamide dinucleotide having any tetrahydronicotinamide and adenosine as the nucleobases as well as an additional phosphate group.


B-Cell Malignant Neoplasm

description: A clonal lymphoproliferative disorder composed of neoplastic B-cells. It includes B-cell non-Hodgkin lymphomas, B-cell leukemias, and plasma cell myeloma.


Chronic lymphocytic leukemia stage 1

description: Risk: Intermediate; Findings: Lymphocytosis and adenopathy; Survival (months): 95. (from AJCC 8th Ed.)


name: Multiple Myeloma with MAF Family Translocation

description: Multiple myeloma characterized by the presence of a translocation involving a MAF family gene.


DS Stage IA Multiple Myeloma

description: Durie/Salmon stage I multiple myeloma associated with a relatively normal renal function (serum creatinine concentration < 2.0 mg/dL).


name: B Acute Lymphoblastic Leukemia with t(4;11)(q21;23.3); KMT2A-AFF1

description: A B-cell acute lymphoblastic leukemia associated with t(4;11)(q21;23.3). This translocation leads to the generation of the fusion gene KMT2A-AFF1.


name: Childhood B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

description: A B acute lymphoblastic leukemia that occurs during childhood. It is characterized by the presence of lymphoblasts that carry a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.


name: Hypodiploid B Acute Lymphoblastic Leukemia

description: A B-cell acute leukemia characterized by the presence of lymphoblasts which contain less than 46 chromosomes. It occurs in both children and adults. It has an unfavorable clinical outcome.


Recurrent Chronic Lymphoid Leukemia

description: The reemergence of chronic lymphocytic leukemia after a period of remission.


name: Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

description: Chronic lymphocytic leukemia/small lymphocytic lymphoma that does not respond to treatment.


name: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

description: The reemergence of chronic lymphocytic leukemia/small lymphocytic lymphoma after a period of remission.


name: Refractory B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

description: B-acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 that is resistant to treatment.


Leptomeningeal myelomatosis

description: A central nervous system multiple myeloma involving the leptomeninges.


name: B Acute Lymphoblastic Leukemia with Recurrent Genetic Abnormalities

description: B-acute lymphoblastic leukemias characterized by the presence of recurring cytogenetic and/or molecular abnormalities.


name: Refractory B Acute Lymphoblastic Leukemia

description: B-acute lymphoblastic leukemia that does not respond to treatment.


Plasma cell myeloma recurrent

description: The reemergence of multiple myeloma after a period of remission.


DS Stage IIIB Multiple Myeloma

description: Durie/Salmon stage III multiple myeloma associated with abnormal renal function (serum creatinine concentration greater than or equal to 2.0 mg/dL).


name: Recurrent B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

description: The reemergence of  B-acute lymphoblastic leukemia, BCR-ABL1-like after a period of remission.


name: B Acute Lymphoblastic Leukemia with ETV6-RUNX1-Like Features

description: B acute lymphoblastic leukemia characterized by a gene-expression profile similar to that of ETV6-RUNX1-positive B acute lymphoblastic leukemia, absence of the pathognomonic ETV6-RUNX1 rearrangement, and rearrangements or deletions of ETV6 and IKZF1 genes.


name: Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder

description: A clonal B-cell lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by destructive infiltration of lymph nodes and extranodal sites by a monotonous population of transformed B-lymphocytes or plasma cells. The clonal cellular infiltrates fulfill the criteria for a diffuse large B-cell lymphoma, Burkitt lymphoma, or a plasma cell neoplasm.


name: Recurrent B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

description: The reemergence of B acute lymphoblastic leukemia, Philadelphia chromosome negative, after a period of remission.


name: Multiple Myeloma, Not Otherwise Specified

description: Multiple myelomas characterized by the absence of recurrent genetic abnormalities.


name: B Acute Lymphoblastic Leukemia, Not Otherwise Specified

description: B-acute lymphoblastic leukemias characterized by the absence of recurrent genetic abnormalities.


name: Extramedullary Disease in Multiple Myeloma Involving the Central Nervous System

description: Multiple myeloma involving the central nervous system. It manifests with single or multiple intraparenchymal lesions and/or leptomeningeal involvement. Patients present with diffuse cerebral dysfunction and nerve paralysis. The prognosis is poor.


Stage A Chronic Lymphocytic Leukemia

description: Findings: Lymphocytosis only; Survival (months): more than 120. (from AJCC 8th Ed.)


name: Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Heavy Chain Variable-Region Gene

description: Chronic lymphocytic leukemia characterized by the absence of somatic hypermutation within the immunoglobulin heavy chain gene variable region of neoplastic clones. Patients have a significantly worse prognosis as compared to those with mutated immunoglobulin heavy chain gene variable region rearrangements.


name: B Acute Lymphoblastic Leukemia with Mutated ZEB2 (p.H1038R)

description: B-acute lymphoblastic leukemia associated with mutations in the ZEB2 gene that encode a histidine to arginine amino acid substitution at codon 1038. This variation appears to phenocopy the IGH-CEBPE gene fusion. This is a provisional entity.


name: Refractory B-Cell Prolymphocytic Leukemia

description: B-cell prolymphocytic leukemia that is resistant to treatment.


name: Chronic Lymphocytic Leukemia- Binet Staging System

description: A term that refers to the staging of chronic lymphocytic leukemia according to Binet staging system. This system is in wide use outside the United States.


Chronic lymphocytic leukemia stage 4

description: Risk: High; Findings: Lymphocytosis and platelets less than 100,000/microliter; Survival (months): 30. (from AJCC 8th Ed.)


name: Cutaneous B Lymphoblastic Leukemia/Lymphoma

description: B-lymphoblastic leukemia/lymphoma that affects the skin.


Recurrent Extraosseous Plasmacytoma

description: The reemergence of extraosseous plasmacytoma after a period of remission.


Recurrent Solitary Plasmacytoma

description: The reemergence of solitary plasmacytoma after a period of remission.


Stage B Chronic Lymphocytic Leukemia

description: Findings: Lymphocytosis and adenopathy; Survival (months): 95. (from AJCC 8th Ed.)


name: Multiple Myeloma Post-Transplant Lymphoproliferative Disorder

description: A lymphoproliferative disorder that develops following an organ transplantation and exhibits multiple myeloma features.


name: Multiple Myeloma with Recurrent Genetic Abnormalities

description: Multiple myelomas characterized by the presence of recurring cytogenetic abnormalities.


name: Plasmacytoma-Like Post-Transplant Lymphoproliferative Disorder

description: A plasmacytoma-like hematologic malignancy that arises in a patient with a history of organ transplantation.


name: B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 with Multilineage Involvement

description: B-acute lymphoblastic leukemia associated with t(9;22)(q34.1;q11.2); BCR-ABL1 and characterized by both lymphoblastic and differentiating myeloid cell proliferation.


name: B Acute Lymphoblastic Leukemia with Germline IKZF1 Mutation

description: B-acute lymphoblastic leukemia that results from germline mutation of the IKZF1 gene.


Chronic lymphocytic leukemia stage 2

description: Risk: Intermediate; Findings: Lymphocytosis, adenopathy, and enlarged spleen and/or liver; Survival (months): 72. (from AJCC 8th Ed.)


name: Adult B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

description: A B acute lymphoblastic leukemia that occurs during adulthood. It is characterized by the presence of lymphoblasts that carry a translocation between the BCR gene on chromosome 22 and the ABL1 gene on chromosome 9. It results in the production of the p190 kd or p210 kd fusion protein. It has an unfavorable clinical outcome.


Refractory B-Cell Malignant Neoplasm

description: A B-cell malignant neoplasm that is resistant to treatment.


name: Multiple Myeloma with CCND Family Translocation

description: Multiple myeloma characterized by the presence of a translocation involving a CCND family gene.


RISS Stage I Multiple Myeloma

description: Serum beta-2-microglobulin less than 3.5 mg/L and serum albumin 3.5 g/dL or more and no high-risk cytogenetics and normal LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)


DS Stage IIB Multiple Myeloma

description: Durie/Salmon stage II multiple myeloma associated with abnormal renal function (serum creatinine concentration greater than or equal to 2.0 mg/dL).


name: Chronic Lymphocytic Leukemia with Plasmacytoid Differentiation

description: A chronic lymphocytic leukemia characterized by the presence of neoplastic lymphocytes with plasmacytoid morphology.


name: Near-Haploid B Acute Lymphoblastic Leukemia

description: B-acute lymphoblastic leukemia associated with a near haploid karyotype.


name: B Acute Lymphoblastic Leukemia with IKZF1 N159Y Mutation

description: B-acute lymphoblastic leukemia associated with IKZF1 missense mutation p.Asn159Tyr (N159Y).


name: B Acute Lymphoblastic Leukemia with UBTF-ATXN7L3/PAN3, CDX2 ("CDX2/UBTF")

description: B-acute lymphoblastic leukemia associated with concomitant CDX2 deregulation and expression of the chimeric UBTF-ATXN7L3 fusion oncoprotein. It usually affects female adolescents and young adults. The prognosis is poor following treatment with conventional chemotherapy.


name: Extramedullary Disease in Plasma Cell Myeloma

description: Infiltration of organs and soft tissues by malignant (clonal) plasma cells in patients with history of multiple myeloma. Skin, liver, lymph nodes, pleura, and central nervous system are the most frequently affected sites.


Head and Neck Plasmacytoma

description: A plasmacytoma that arises from the head and neck region.


Sinonasal Plasmacytoma

description: A plasmacytoma that arises from the sinonasal tract.


DS Stage IIA Multiple Myeloma

description: Durie/Salmon stage II multiple myeloma associated with a relatively normal renal function (serum creatinine concentration < 2.0 mg/dL).


name: Progressive Hairy Cell Leukemia Initial Treatment

description: A hairy cell leukemia requiring initial treatment because of the presence of signs of progression.  Signs of progression include cytopenia (especially if symptomatic), increasing splenomegaly, and infectious complications.  Therapy is not necessary if the patients are asymptomatic and the blood counts are maintained in an acceptable range.


name: Refractory Transformed Chronic Lymphocytic Leukemia

description: Chronic lymphocytic leukemia which has undergone histologic transformation to an aggressive diffuse large B-cell lymphoma (Richter's transformation) and has become resistant to treatment.


name: B Lymphoblastic Leukemia/Lymphoma with MYC Rearrangement

description: B-lymphoblastic leukemia/lymphoma associated with MYC gene rearrangement. The prognosis is poor.


Primary cutaneous plasmacytoma

description: A plasmacytoma that arises in the skin.


name: B Acute Lymphoblastic Leukemia with PAX5 Alteration

description: B-acute lymphoblastic leukemia associated with PAX5 gene alteration, including rearrangements, point mutations, and intragenic lesions. This is a provisional entity.


name: B Lymphoblastic Leukemia/Lymphoma with TCF3-HLF Rearrangement

description: An exceptionally rare childhood B-lymphoblastic leukemia/lymphoma associated with TCF3-HLF gene rearrangement resulting in the formation of TCF3-HLF chimeric transcription factor. The prognosis is poor.


name: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, JAK-STAT Activated

description: B-acute lymphoblastic leukemia, BCR-ABL1-like associated with aberrant activation of the JAK-STAT signaling pathway.


name: Chronic Lymphocytic Leukemia with Immunoglobulin Heavy Chain Variable-Region Gene Somatic Hypermutation

description: Chronic lymphocytic leukemia characterized by the presence of somatic hypermutation within the immunoglobulin heavy chain gene variable region of neoplastic clones. Patients have a better prognosis as compared to those with unmutated immunoglobulin heavy chain gene variable region rearrangements.


Plasma cell myeloma refractory

description: Multiple myeloma that is resistant to treatment.


Testicular Plasmacytoma

description: A rare plasmacytoma that arises in the testis. At presentation the involvement is usually unilateral.


name: B Acute Lymphoblastic Leukemia with Germline PAX5 Mutation

description: B-acute lymphoblastic leukemia that results from germline mutation of the PAX5 gene.


DS Stage II Plasma Cell Myeloma

description: Multiple myeloma that fits in neither stage I nor stage III.  Estimated myeloma cell mass: 0.6 to 1.2 trillion (1012)/m2 (intermediate burden).  The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL, b. Creatinine greater than or equal to 2.0 mg/dL.  Impaired renal function worsens prognosis regardless of stage.  Note that the newer International Staging System defines stage II quite differently: Beta-2-microglobulin less than 3.5 and albumin less than 3.5 or beta-2-microglobulin 3.5 to less than 5.5 (median survival of 44 months).  (PDQ)


name: B Acute Lymphoblastic Leukemia with MEF2D Rearrangement

description: B-acute lymphoblastic leukemia associated with MEF2D gene rearrangement. The prognosis is poor.


Chronic lymphocytic leukemia refractory

description: Chronic lymphocytic leukemia that is resistant to treatment.


name: Transformed Chronic Lymphocytic Leukemia to Hodgkin Lymphoma

description: Histologic transformation of chronic lymphocytic leukemia to Hodgkin lymphoma.


name: Recurrent B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

description: The reemergence of B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 after a period of remission.


name: Extramedullary Disease in Multiple Myeloma Involving the Uterine Corpus

description: Infiltration of the uterine corpus by malignant (clonal) plasma cells in patients with history of multiple myeloma.


name: Childhood B Lymphoblastic Leukemia/Lymphoma

description: B lymphoblastic leukemia/lymphoma that occurs during childhood.


Multiple Myeloma with t(11;14)(q13;q32)

description: Multiple myeloma characterized by the presence of t(11;14)(q13;q32). It is the most common immunoglobulin heavy chain translocation found in multiple myeloma and results in CCND1 overexpression.


name: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

description: B acute lymphoblastic leukemia characterized by a gene-expression profile similar to that of BCR-ABL1-positive B acute lymphoblastic leukemia, absence of the pathognomonic BCR-ABL1 rearrangement, alterations of lymphoid transcription factor genes, and a poor outcome.


name: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, ABL1 Rearranged

description: B-acute lymphoblastic leukemia, BCR-ABL1-like associated with ABL1 gene rearrangement.


name: Chronic Lymphocytic Leukemia- Modified Rai Staging System

description: A term that refers to the staging of chronic lymphocytic leukemia according to modified Rai staging system. This system is mainly used in North America.


Chronic lymphocytic leukemia stage 3

description: Risk: High; Findings: Lymphocytosis and hemoglobin less than 11 g/dL; Survival (months): 30. (from AJCC 8th Ed.)


RISS Stage II Multiple Myeloma

description: Not stage I or III. (from AJCC 8th Ed.)


name: Low-Hypodiploid B Acute Lymphoblastic Leukemia

description: B-acute lymphoblastic leukemia associated with a low hypodiploid karyotype.


Multiple Myeloma by ISS Stage

description: A header term that refers to the staging of multiple myeloma according to the International Staging System.


Recurrent Burkitt Leukemia

description: The reemergence of Burkitt leukemia after a period of remission.


name: Plasma Cell Post-Transplant Lymphoproliferative Disorder

description: A plasma cell neoplasm that arises in a patient with a history of organ transplantation.


Multiple Myeloma by RISS Stage

description: A staging system for multiple myeloma based on the Revised International Staging System (RISS) criteria. This staging system does not apply to smoldering multiple myeloma (no AJCC staging system), monoclonal gammopathy of undetermined significance (no AJCC staging system), and Waldenstrom macroglobulinemia (no AJCC staging system). (from AJCC 8th Ed.)


name: B Acute Lymphoblastic Leukemia with Germline Predisposition

description: B-acute lymphoblastic leukemia that results from germline gene mutations. This category includes B-acute lymphoblastic leukemia with germline PAX5 mutation and B-acute lymphoblastic leukemia with germline IKZF1 mutation.


Adult Burkitt Leukemia

description: The leukemic counterpart of Burkitt lymphoma occurring in adults.  The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood.  This is an aggressive leukemia.


ISS Stage II Plasma Cell Myeloma

description: Multiple myeloma with blood levels of beta-2-microglobulin between 3.5 and 5.5 mg/L.


Recurrent B-Cell Malignant Neoplasm

description: The reemergence of a B-cell malignant neoplasm after a period of remission.


Plasmacytoma anaplastic

description: A plasmacytoma characterized by the presence of malignant plasma cells with anaplastic features.


name: B Acute Lymphoblastic Leukemia with MYC Rearrangement

description: B-acute lymphoblastic leukemia associated with MYC gene rearrangement. The prognosis is poor.


Refractory Burkitt Leukemia

description: Burkitt leukemia resistant to treatment.


name: Multiple Myeloma with NSD2 Translocation

description: Multiple myeloma characterized by the presence of a translocation involving the NSD2 gene.


name: Recurrent Transformed Chronic Lymphocytic Leukemia

description: The reemergence of chronic lymphocytic leukemia transformed to aggressive diffuse large B-cell lymphoma (Richter's transformation) after a period of remission.


name: Extramedullary Disease in Multiple Myeloma Involving the Skin

description: Infiltration of the skin by malignant (clonal) plasma cells in patients with history of multiple myeloma.


Advanced B-Cell Malignant Neoplasm

description: A B-cell malignant neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: B Acute Lymphoblastic Leukemia with ZNF384 Rearrangement

description: B-acute lymphoblastic leukemia associated with ZNF384 gene rearrangement. The prognosis is variable.


name: B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 with Lymphoid Only Involvement

description: B-acute lymphoblastic leukemia associated with t(9;22)(q34.1;q11.2); BCR-ABL1 and characterized by lymphoblastic proliferation without differentiating myeloid cell proliferation.


Stage C Chronic Lymphocytic Leukemia

description: Findings: Lymphocytosis, adenopathy, and enlarged spleen and/or liver; Survival (months): 72. (from AJCC 8th Ed.)


Cutaneous Chronic Lymphocytic Leukemia

description: A chronic lymphocytic leukemia that affects the skin.


DS Stage III Plasma Cell Myeloma

description: Multiple myeloma with one or more of the following: 1. Hemoglobin less than 8.5 g/dL. 2. Serum calcium greater than 12.0 mg/dL. 3. More than three lytic bone lesions. 4. High M protein production as shown by: a. IgG greater than 7.0 g/dL. b. IgA greater than 5.0 g/dL. c. Urinary kappa or lamda greater than 12.0 g/24 hours. Estimated myeloma cell mass: greater than 1.2 trillion (1012)/m2 (high burden). The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL. b. Creatinine greater than or equal to 2.0 mg/dL. Serum beta-2-microglobulin has been shown to be a reliable marker for prognosis. Since the great majority of symptomatic myeloma patients are classified as stage III by the Durie/Salmon criteria, this staging system has not proven to be very useful for identifying the patients with intermediate and poor prognosis. Note that the newer International Staging System defines stage III quite differently: Beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months). (PDQ)


DS Stage I Plasma Cell Myeloma

description: Multiple myeloma with all of the following: 1. Hemoglobin greater than 10 g/Dl, 2. Normal serum calcium, 3. Normal bone structure, 4. Low monoclonal (or myeloma) protein (M protein) production as shown by: a. IgG less than 5.0 g/dL, b. IgA less than 3.0 g/dL, c. Urinary kappa or lamda less than 4 g/24 hours. Estimated myeloma cell mass: less than 0.6 trillion (1012)/m2 (low burden). The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL, b. Creatinine greater than or equal to 2.0 mg/dL. Impaired renal function worsens prognosis regardless of stage. Note that the newer International Staging System defines stage I quite differently: Beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months). (PDQ)


name: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

description: A B-acute lymphoblastic leukemia (B-ALL) that does not have the cytogenetic abnormality t(9;22)(q34;q11.2). Most cases of B-ALL do not have this translocation.


DS Stage IIIA Multiple Myeloma

description: Durie/Salmon stage III multiple myeloma associated with a relatively normal renal function (serum creatinine concentration < 2.0 mg/dL).


name: B Lymphoblastic Leukemia/Lymphoma with ETV6-RUNX1-Like Features

description: B lymphoblastic leukemia/lymphoma characterized by a gene-expression profile similar to that of ETV6-RUNX1-positive B lymphoblastic leukemia/lymphoma, absence of the pathognomonic ETV6-RUNX1 rearrangement, and rearrangements or deletions of ETV6 and IKZF1 genes.


name: Recurrent B Acute Lymphoblastic Leukemia

description: The reemergence of B acute lymphoblastic leukemia after a period of remission.


RISS Stage III Multiple Myeloma

description: Serum beta-2-microglobulin 5.5 mg/L or more and high-risk cytogenetics and/or high LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)


name: B Acute Lymphoblastic Leukemia Associated with Down Syndrome

description: A B-acute lymphoblastic leukemia that occurs in patients with Down syndrome. It usually affects young children, but it can occur in adults as well. It has an unfavorable clinical outcome. Cases of T-acute lymphoblastic leukemia in patients with Down syndrome have not been reported.


name: Hyperdiploid B Acute Lymphoblastic Leukemia

description: A B-cell acute leukemia characterized by the presence of lymphoblasts which contain more than 50 and usually less than 66 chromosomes. It is commonly seen in children and rarely in adults. It has a favorable clinical outcome.


name: B Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified

description: B-lymphoblastic leukemias/lymphomas characterized by the absence of recurrent genetic abnormalities.


name: B Acute Lymphoblastic Leukemia with NUTM1 Rearrangement

description: B-acute lymphoblastic leukemia associated with NUTM1 gene rearrangement. The prognosis is good.


ISS Stage III Plasma Cell Myeloma

description: Multiple myeloma with beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months).  Note that the older Durie/Salmon staging system defines stage III quite differently. (PDQ)


DS Stage IB Multiple Myeloma

description: Durie/Salmon stage I multiple myeloma associated with abnormal renal function (serum creatinine concentration greater than or equal to 2.0 mg/dL).


name: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, ABL Class Rearranged

description: B-acute lymphoblastic leukemia, BCR-ABL1-like associated with rearrangement of an ABL class gene (e.g., ABL1, ABL2, CSF1R, PDGFRA, and PDGFRB).


name: Recurrent B-Cell Prolymphocytic Leukemia

description: The reemergence of a B-cell prolymphocytic leukemia after a period of remission.


name: Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma

description: Histologic transformation of an indolent chronic lymphocytic leukemia to an aggressive diffuse large B-cell lymphoma.


name: Extramedullary Disease in Multiple Myeloma Involving the Kidney

description: Infiltration of the kidney by malignant (clonal) plasma cells in patients with history of multiple myeloma.


Multiple Myeloma with Hyperdiploidy

description: Multiple myeloma characterized by the presence of plasma cells in which the chromosomal number is greater than the normal diploid number.


Chronic lymphocytic leukemia stage 0

description: Risk: Low; Findings: Lymphocytosis only; Survival (months): more than 120. (from AJCC 8th Ed.)


name: Refractory B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

description: B acute lymphoblastic leukemia, Philadelphia chromosome negative, that does not respond to treatment.


name: B Acute Lymphoblastic Leukemia with ZNF362 Rearrangement

description: B-acute lymphoblastic leukemia associated with ZNF362 gene rearrangement. The prognosis is variable.


name: Refractory B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

description: B-acute lymphoblastic leukemia, BCR-ABL1-like that does not respond to treatment.


ISS Stage I Plasma Cell Myeloma

description: Multiple myeloma with beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months).  Note that the older Durie/Salmon staging system defines stage I quite differently. (PDQ)


name: B-lymphoblastic leukemia lymphoma BCR-ABL1-like

description: B lymphoblastic leukemia/lymphoma characterized by a gene-expression profile similar to that of BCR-ABL1-positive B lymphoblastic leukemia/lymphoma, absence of the pathognomonic BCR-ABL1 rearrangement, alterations of lymphoid transcription factor genes, and a poor outcome.


name: B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Not Otherwise Specified

description: B-acute lymphoblastic leukemia, BCR-ABL1-like in which further genetic/molecular characterization is not available.


Multiple Myeloma Myeloma by DS Stage

description: A header term that refers to the staging of multiple myeloma according to the Durie/Salmon staging system.


Childhood Burkitt Leukemia

description: The leukemic counterpart of Burkitt lymphoma occurring in children.  The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood.  This is an aggressive leukemia.


name: Sedative, Hypnotic or Anxiolytic Dependence with Unspecified Disorder

description: Evidence of sedative, hypnotic or anxiolytic dependence with unspecified disorder.


SODIUM FERULATE

An organic sodium salt resulting from the replacement of the proton from the 3-hydroxy group of ferulic acid by a sodium ion.


Nasal Cavity Neuroendocrine Neoplasm

description: A neuroendocrine neoplasm that arises from the nasal cavity.


Nasal Cavity Neuroendocrine Carcinoma

description: A neuroendocrine carcinoma that arises from the nasal cavity.


name: Nasal Cavity Large Cell Neuroendocrine Carcinoma

description: A large cell neuroendocrine carcinoma that arises from the nasal cavity.


name: Nasal Cavity Small Cell Neuroendocrine Carcinoma

description: A small cell neuroendocrine carcinoma that arises from the nasal cavity.


name: Intrahepatic Bile Duct Cancer pM1 TNM Finding v8

description: Intrahepatic bile duct cancer with distant metastasis. (from AJCC 8th Ed.)


A member of the class of  methylpyridines that is pyridine carrying methyl substituents at positions 2 and 6.


name: Penile Undifferentiated Pleomorphic Sarcoma

description: A rare undifferentiated pleomorphic sarcoma that occurs in the penis.


Primary Site Unknown

description: Referring to the fact that the original site of growth of a metastatic cancer is unknown or uncertain.


name: Grade 1 Scrotum Intra-Operative Injury, CTCAE


An L-tryptophan derivative that is the 7-(3,3-dimethylallyl) derivative of L-tryptophan.


Non-Neoplastic Vision Disorder

description: A non-neoplastic disorder that causes a disturbance in normal vision. Representative examples include amblyopia, astigmatism, myopia, and cataracts.


Color Blindness, Inherited

description: Genetic based difficulty in distinguishing colors.


Optical Illusion

description: The visual perception of an image that differs from the reality of the image.


CDP-alpha-D-abequose

A CDP-D-abequose in which the anomeric centre of the pyranose fragment has alpha-configuration.


trifluoro-L-methionine

An L-alpha-amino acid, methionine, with the S-methyl group trifluoro-substituted.


victoria blue R

An iminium salt composed of 4-{[4-(dimethylamino)phenyl][4-(ethylamino)naphthalen-1-yl]methylidene}-N,N-dimethylcyclohexa-2,5-dien-1-iminium and chloride ions in a 1:1 ratio.


A member of the class of pretetramides that is 6-methyltetracene-2-carboxamide carrying six hydroxy substituents at positions 1, 3, 4, 10, 11 and 12.


A member of the class of pretetramides in which the only additional substituent is a methyl group at position 6.


name: Advanced Extracranial Malignant Solid Neoplasm

description: A malignant solid neoplasm that arises from any anatomic site other than the brain and has spread extensively to other anatomic sites or is no longer responding to treatment.


(6Z,9Z)-octadecadienoic acid

An octadecadienoic acid in which the two double bonds have Z-geochemistry and are located at positions 6 and 9.


indole-5,6-quinone-2-carboxylic acid

An indoledione that is 1H-indole-5,6-dione substituted by a carboxy group at position 2.


DIMEDAZOL

A dimethylbenzimidazole carrying methyl substituents at positions 5 and 6.


A beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine in which the acyl group specified is hexadecanoyl.


name: Narrowed Filtration Angle of Trabecular Meshwork

description: A smaller than normal angle between the sclerocorneal junction and the iris at the periphery of the anterior chamber of the eye, which is the main exit site for aqueous fluid.


name: alcohol dependence with withdrawal with perceptual disturbance

description: Evidence of alcohol dependence withdrawal with perceptual disturbance.


Ciliary Body Adenocarcinoma

description: An adenocarcinoma arising from the pigmented or non-pigmented ciliary epithelium.


Stage IIB Uveal Melanoma AJCC v7

description: Stage IIB includes: (T2b, N0, M0); (T3a, N0, M0).  T2b: Ciliary body and choroid: Tumor size category 2 with ciliary body involvement.  T3a: Iris: Tumor confluent with or extending into the ciliary body, choroid, or both, with sclera extension and secondary glaucoma. Ciliary body and choroid: Tumor size category 3 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage IIA Uveal Melanoma AJCC v7

description: Stage IIA includes: (T1b-d, N0, M0); (T2a, N0, M0). T1b: Iris: Tumor limited to the iris more than 3 clock hours in size.  Ciliary body and choroid: Tumor size category 1 with ciliary body involvement.  T1c: Iris: Tumor limited to the iris with secondary glaucoma.  Ciliary body and choroid: Tumor size category 1 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter.  T1d: Ciliary body and choroid: Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. T2a: Iris: Tumor confluent with or extending into the ciliary body, choroid, or both, with secondary glaucoma.  Ciliary body and choroid: Tumor size category 2 without ciliary body involvement and extraocular extension. N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Metastatic Choroid Melanoma

description: Choroid melanoma that has spread from its primary site to another anatomic site.


name: Metastatic Malignant Neoplasm in the Uvea

description: A malignant neoplasm that has spread to the uvea from another anatomic site.


Uveal Melanocytoma

description: A subtype of ciliary body, iris, and choroidal nevi. It is intensely pigmented and composed of large, plump, polyhedral cells.


Choroid Spindle Cell Type A Melanoma

description: A choroid melanoma characterized by the presence of malignant spindle-shaped melanocytes with slender nuclei and no visible nucleoli.


name: Uveal Melanoma by Gene Expression Profile


name: Locally Advanced Unresectable Uveal Melanoma

description: Uveal melanoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.


Uveal Spindle Cell Type A Melanoma

description: A uveal melanoma characterized by the presence of malignant spindle-shaped melanocytes with slender nuclei and no visible nucleoli.


Stage III Uveal Melanoma AJCC v7

description: Stage III includes: IIIA (T2c-d, N0, M0); (T3b-c, N0, M0); (T4a, N0, M0); IIIB (T3d, N0, M0); (T4b-c, N0, M0); IIIC (T4d-e, N0, M0).  T2c: Ciliary body and choroid: Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter. T2d: Ciliary body and choroid: Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. T3b: Ciliary body and choroid: Tumor size category 3 with ciliary body involvement. T3c: Ciliary body and choroid: Tumor size category 3 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter. T4a: Iris: Tumor with extrascleral extension less than or equal to 5 mm in diameter.  Ciliary body and choroid: Tumor size category 4 without ciliary body involvement and extraocular extension.  T3d: Ciliary body and choroid: Tumor size category 3 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter.  T4b: Iris: Tumor with extrascleral extension more than 5 mm in diameter.  Ciliary body and choroid: Tumor size category 4 with ciliary body involvement.  T4c: Ciliary body and choroid: Tumor size category 4 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter.  T4d: Ciliary body and choroid: Tumor size category 4 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter.  T4e: Ciliary body and choroid: Any tumor size category with extraocular extension more than 5 mm in diameter.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Uveal Class 2 Melanoma

description: Gene expression profiling that classifies uveal melanomas into a high-grade group.


Uveal Class 1a Melanoma

description: Uveal melanoma with low metastatic risk as defined by gene expression profiling.


Ciliary Body Nevus

description: A benign nevus that arises from the ciliary body. Only a small percentage of cases progress to ciliary body melanoma.